Portfolio of Cancer Immunotherapy Stocks

Here are 17 cancer immunotherapy stocks.


17 Cancer Immunotherapy Stocks

Name & Return

Symbol
& Snapshot

Amgen AMGN
AstraZeneca AZN
BeiGene Ltd.  BGNE
Bellicum Pharmaceuticals BLCM
bluebird bio BLUE
Bristol-Myers Squibb BMY
Celldex Therapeutics CLDX
Cellectis CLLS
Celyad CYAD
Compugen Ltd. CGEN
Curis CRIS
CytomX Therapeutics CTMX
Gilead Sciences GILD
Incyte Corporation INCY
Merck MRK
Nektar Therapeutics NKTR
Novartis NVS
Display Price Chart for each stock.
Display Dividend Chart for each stock.

Portfolio Values

To inspect the performance of the Cancer Immunotherapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Alpha Vantage.

All 17 stocks are included in the portfolio computations. The current value of the portfolio assumes that $588.24 was invested in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends.

The current value of the $10,000 investment is $13,568. The percent return is 35.68%. The annualized return is 6.29%.



Portfolio Value Chart for Last 100 Daily Closes


Related Portfolios

Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks

Portfolio of Biotech Stocks

Portfolio of Immune Checkpoint Inhibitor Stocks